Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268012 | 0.87 | ALOX5 (0.50) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL25317826 | 0.84 | LMNA (0.55) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL25317372 | 0.81 | AR (0.47) | MAOBMEN1KMT2AALOX5CTSV | |
| SCHEMBL14293620 | 0.78 | MAPT (0.56) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL21538105 | 0.76 | ALOX5 (0.51) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL15472489 | 0.75 | ALOX5 (0.56) | MAOBALOX5LMNACYP1A2PTGS1 | |
| SCHEMBL16822503 | 0.75 | APP (0.52) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL16822606 | 0.75 | MAOB (0.56) | MAOBMEN1KMT2AALOX5LMNA | |
| SCHEMBL2023883 | 0.75 | LMNA (0.58) | MAOBALOX5LMNACYP1A2PTGS1 | |
| SCHEMBL1337716 | 0.75 | MAOB (0.56) | MAOBMEN1KMT2AALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MAOB 775/4885MEN1 457/4885KMT2A 4715/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | MAOB 697/4885MEN1 515/4885KMT2A 4701/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | MAOB 775/4885MEN1 457/4885KMT2A 4715/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | MAOB 697/4885MEN1 515/4885KMT2A 4701/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | MAOB 697/4885MEN1 515/4885KMT2A 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.